A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms.
OBJECTIVE
To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies.


METHODS
The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features.


RESULTS
The incidence of HR was 14% (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02-1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01-0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78-8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94-12.45, p = 0.06, for the taxane model).


CONCLUSIONS
We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.
Department of Gynecologic Oncology, AO Mauriziano Umberto I, University of Turin,Turin, Italy. piovano.elisa@gmail.com
Elisa
E
Piovano
E
E
Pivetta
P
P
Modaffari
F
F
Martra
C
C
Baima Poma
S
S
Perotto
E
E
Tripodi
V
V
Zanfagnin
P
P
Zola
A
A
Ferrero
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D015331:Cohort Studies; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000453:epidemiology; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D015999:Multivariate Analysis; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use; D010386:Pelvic Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors
D000970:Antineoplastic Agents; D017671:Platinum Compounds; D017239:Paclitaxel